Oral Probenecid for Nonhospitalized Adults with Symptomatic Mild-to-Moderate COVID-19

Abstract: Probenecid is an orally bioavailable, uricosuric agent that was first approved in 1951 for the treatment of gout, but was later found to have potent, broad-spectrum antiviral activity against several respiratory viruses, including SARS-CoV-2. We conducted a phase 2 randomized, placebo-controlled, single-blind, dose-range finding study in non-hospitalized patients with symptomatic, mild-to-moderate COVID-19.

The release as fetched from its publisher. trippbio.com ↗